What Is in a Label? The Importance of Clinical Specificity and Challenges of Diagnostic Evolution in Progressive...

This viewpoint addresses the complexity of the nomenclature of progressive speech-language disorders, which often exists at the intersection of descriptive symptoms, clinical syndromes, and underlying neuropathology. Using primary progressive apraxia of speech (PPAOS) as an example, we explore how overlapping diagnostic frameworks employed by speech-language pathologists, neurologists, and other clinicians and researchers can lead to different diagnostic labels that may evolve throughout disease progression. These discrepancies and changes can complicate patient understanding, clinical care, and affect eligibility for clinical trials. We highlight the importance of diagnostic specificity, flexibility, and multidisciplinary collaboration in improving patient counseling, prognostication, treatment planning, and clinical research alignment, particularly in the context of the growing number of clinical trials and specialized, multidisciplinary clinics.

This viewpoint explores how symptom-based, syndrome-based, and pathology-based diagnoses can work together to support patient care and research. Accurate and specific diagnosis of speech-language disorders has important implications for patient understanding of their condition, identity, prognostic accuracy, access to care, clinical trial enrollment, and treatment planning and efficacy. Misdiagnosis or vague labeling can result in inappropriate interventions, delayed support, and skewed research findings. We argue that multidisciplinary collaboration and flexibility in recognizing evolving symptom-based and syndrome-based labels over the disease course-and as the fields learn more-is essential to empower patients with accurate, actionable information. Embracing both the specificity and the complexity of progressive speech-language disorders can both enhance communication and facilitate research.